Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc.

MEDXF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$119.98M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Medexus Pharmaceuticals Inc.Medexus Pharmaceuticals Inc.-94.7--3%1.30.5
$7.00

Target Price by Analysts

84.2% upsideMedexus Pharmaceuticals Target Price DetailsTarget Price
$1.05

Current Fair Value

72.2% downside

Overvalued by 72.2% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$119.98 Million
Enterprise Value$137.80 Million
Earnings per Share$-0.07
Beta1.68
Outstanding Shares31,430,748

Return

Return on Equity-2.61%ROE
Return on Assets-0.86%
Return on Invested Capital4.51%

Valuation & Multiples

P/E Ratio-94.66P/E Ratio
PEG26.76PEG
Price to Sales1.27Price to Sales
Price to Book Ratio3.8Price to Book Ratio
Enterprise Value to Revenue1.29
Enterprise Value to EBIT32.16
Enterprise Value to Net Income-109
Total Debt to Enterprise0.19
Debt to Equity0.54Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 11, 2026
EPS
$0.03
Est. $0.02
Revenue
$29.10 M
Est. $26.82 M

Next Earnings Call

Expected Date
February 10, 2027
EPS Estimate
$0.07
Consensus analyst estimate
Revenue Estimate
$30.80 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Medexus Pharmaceuticals Inc.

90 employees
CEO: Kenneth d'Entremont

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. I...

Questions & Answers